Mechanism of Zhinao Capsule in Treating Alzheimer’s Disease Based on Network Pharmacology Analysis and Molecular Docking Validation

Abstract

Objective. This study aimed to determine the active components of Zhinao capsule (ZNC) and the targets in treating Alzheimer’s disease (AD) so as to investigate and explore the mechanism of ZNC for AD. Methods. The active components and targets of ZNC were determined from the traditional Chinese medicine systems pharmacology database (TCMSP). The target genes of AD were searched for in GeneCards. Cytoscape was used to construct an herb-component-target-disease network. A protein-protein interaction (PPI) network was constructed by STRING. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the OmicShare. UCSF Chimera and SwissDock were used for molecular docking verification. Finally, four key target genes were validated by Western blotting. Results. In total, 55 active components, 287 targets of active components, 1197 disease genes, and 134 common genes were screened, which were significantly enriched in 3975 terms of biological processes (BP), 284 terms of cellular components (CC), 433 terms of molecular functions (MF), and 245 signaling pathways. Caspase-3 (CASP3) and beta-sitosterol, tumor necrosis factor-alpha (TNF-α) and quercetin, vascular endothelial growth factor A (VEGFA) and baicalein, and mitogen-activated protein kinase 1 (MAPK1) and quercetin showed good-to-better docking. Moreover, ZNC not only downregulated CASP3 and TNF-α protein expression but also upregulated the protein expression of VEGFA and MAPK1. Conclusions. The active components of ZNC, such as beta-sitosterol, quercetin, and baicalein may act on multiple targets like CASP3, VEGFA, MAPK1, and TNF-α to affect T cell receptor (TCR), TNF, and MAPK signaling pathway, thereby achieving the treatment of AD. This study provides a scientific basis for further exploring the potential mechanism of ZNC in the treatment of AD and a reference for its clinical application.

Exploration of Underlying Mechanisms for Modified Xi-Xin-TangIII in Treating Alzheimer’s Disease through Network Integration Investigation

“…Globally, researchers are making numerous attempts in the eld. Formulae of TCM including XXTIII and mXXTIII are widely used to treat AD (Howes et al, 2017;Ma et al, 2022;Zhang et al, 2022) and their e cacy has been con rmed in several experiments (Diwu et al, 2013a;. Owing to multiple ingredients, targets and action pathways of formulae, the speci c molecular biology of mXXTIII against AD remains unclear.…”